Show Summary Details
Page of

Colorectal cancer 

Colorectal cancer
Colorectal cancer

Alex Boussioutas

, Stephen Fox

, Iris Nagtegaal

, Alexander Heriot

, Jonathan Knowles

, Michael Michael

, Sam Ngan

, Kathryn Field

, and John Zalcberg



New material added includes a pooled analysis study and a quality of life study

Clarified the SBRT procedure

Takes into account a recent meta-analysis which confirmed the modest benefit in disease-free survival for post-operative adjuvant chemotherapy in patients with resected Stage II colon cancer

Risk stratification of patients with resected stage II colon cancer further optimised: the number of high risk factors associated with an increase in overall and disease specific mortality and hence possibly the need for adjuvant chemotherapy

Confirmation by another phase III trial of the equivalency of CAPOX versus FOLOFX in the adjuvant therapy of patients with high risk Stage II and Stage III colon cancer.

Small heterogeneous studies indicate that adding oxaliplatin to 5FU-based adjuvant chemotherapy may overcome the negative impact of 5-FU on colon cancers with the MSI-H/dMMR genotype.

Utility of ctDNA for molecular testing

Updated on 25 May 2017. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 13 July 2020

This chapter covers colorectal cancer, and includes information on epidemiology, risk factors (chronic inflammation/inflammatory bowel disease, radiation, diet and lifestyle, post cholecystectomy, diabetes, obesity and insulin resistance, cigarette smoking, alcohol, ureterocolic anastamosis, and genetic risk factors, screening, and chemoprevention (aspirin, and NSAIDS), the molecular biology and pathology of colorectal cancer, colorectal carcinoma (location, pathologic prognostic markers, and predictive markers), surgical management (colonic cancer and inflammatory bowel disease, hereditary non-polyposis colonic cancer or HNPCC, presenting as an emergency, treatment of polyp or early cancers, liver and lung metastasis, peritoneal disease, results of surgery and treatment for colon cancer, medical management of early stage disease, adjuvant chemotherapy for stage III disease (T1-4, N1-2M0), adjuvant therapy of patients with resected stage II colon cancer, radiotherapy, multidisciplinary care and special groups, the role of allied teams, and surveillance and follow-up.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.